《强生（Johnson & Johnson）：2024年美国药品定价透明度报告：患者可及性和可负担性（英文版）（10页）.pdf》由会员分享，可在线阅读，更多相关《强生（Johnson & Johnson）：2024年美国药品定价透明度报告：患者可及性和可负担性（英文版）（10页）.pdf（10页珍藏版）》请在三个皮匠报告上搜索。

1、 Johnson&Johnson and its affiliates 2025 07/25 cp-509115v22024 Johnson&Johnson Innovative Medicine U.S.pricing transparency dataPatient access and affordabilityLearn more at Johnson&JohnsonU.S.pricing transparency dataEven with lower net prices for middlemen,premiums and deductibles continue to grow

2、 for individuals and families.3 Access restriction tools like strict prior authorization,step therapy and exclusion lists are making it harder for patients to get lifesaving medicines.4Patients need more affordable access,fewer restrictionsMore invested in R&D in 2024 compared to sales and marketing

3、1124%Our total R&D spending for 2024,bringing J&J Innovative Medicine R&D spending to over$90B since 20161$13.5BIn 2024,J&J provided$47.8Bin rebates,discounts and fees1$47.8BIn 2024,J&J provided 58%oftotal gross sales to the healthcare system through rebates,discounts and fees158%By the numbersNearl

4、y half of this total goes to the 340B Program,private health insurers and pharmacy benefit managers(PBMs),whose rebates and discounts have risen significantly since 2016.1Rebates,discounts and fees totaled$47.8B in 20241The changes in our net prices are below overall inflation growth,and are signifi

5、cantly below the change in our list prices.Our average net prices have declined a compounded 18.2%since 20161J&J Innovative Medicines continuous R&D investments,totaling over$90 billion since 2016,are helping save lives today and bringing hope to patients tomorrow.1 Yet,patients affordable access to

6、 lifesaving medicines is becoming harder each year because of increasing out-of-pocket costs,inadequate insurance benefit design and regulatory hurdles.2J&J Innovative Medicine is leading where medicine is goingAt a glance:Growth in rebates,discounts and fees1$7.4B$7.1B$5.6B$14.7B$1.7B340B programMe